This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hanekamp, E. E. Articles by Blok, L. J. Search for Related Content PubMed PubMed Citation Articles by Hanekamp, E. E. Articles by Blok, L. J.

Consequences of Loss of Progesterone Receptor Expression in Development of Invasive Endometrial Cancer¹

Departments of Reproduction and Development [E. E. H., L. C. M. K., P. E. d. R., A. O. B., J. A. G., L. J. B.], Gynecology and Obstetrics [S. C. J. P. G., E. S-K., C. W. B., F. J. H.], and Pathology [S. C-A.], Erasmus MC, Rotterdam, the Netherlands

Purpose: In endometrial cancer, loss of progesterone receptors (PR) is associated with more advanced disease. This study aimed to investigate the mechanism of action of progesterone and the loss of its receptors (PRA and PRB) in development of endometrial cancer.

Experimental Design: A 9600-cDNA microarray analysis was performed to study regulation of gene expression in the human endometrial cancer subcell line Ishikawa PRAB-36 by the progestagen medroxy progesterone acetate (MPA). Five MPA-regulated genes were selected for additional investigation. Expression of these genes was studied by Northern blot and by immunohistochemistry in Ishikawa subcell lines expressing different PR isoforms. Additionally, endometrial cancer tissue samples were immunohistochemically stained to study the in vivo protein expression of the selected genes.

Results: In the PRAB-36 cell line, MPA was found to regulate the expression of a number of invasion- and metastasis-related genes. On additional investigation of five of these genes (CD44, CSPG/Versican, Tenascin-C, Fibronectin-1, and Integrin-ß 1), it was observed that expression and progesterone regulation of expression of these genes varied in subcell lines expressing different PR isoforms. Furthermore, in advanced endometrial cancer, it was shown that loss of expression of both PR and E-cadherin was associated with increased expression CD44 and CSPG/Versican.

Conclusion: The present study shows that progestagens exert a modulatory effect on the expression of genes involved in tumor cell invasion. As a consequence, loss of PR expression in human endometrial cancer may lead to development of a more invasive phenotype of the respective tumor.

This article has been cited by other articles:

				J Kodama, Hasengaowa, T Kusumoto, N Seki, T Matsuo, Y Ojima, K Nakamura, A Hongo, and Y Hiramatsu Prognostic significance of stromal versican expression in human endometrial cancer Ann. Onc., February 1, 2007; 18(2): 269 - 274. [Abstract] [Full Text] [PDF]

				H. Zhu, P.C.K. Leung, and C.D. MacCalman Expression of ADAMTS-5/implantin in human decidual stromal cells: regulatory effects of cytokines Hum. Reprod., January 1, 2007; 22(1): 63 - 74. [Abstract] [Full Text] [PDF]

				P. E. Schwartz Progesterone Isoforms and Endometrial Cancer Reproductive Sciences, May 1, 2005; 12(4): 219 - 221. [PDF]

				E. E. Hanekamp, S. C.J.P. Gielen, P. E. De Ruiter, S. Chadha-Ajwani, F. J. Huikeshoven, C. W. Burger, J. A. Grootegoed, and L. J. Blok Differences in Invasive Capacity of Endometrial Cancer Cell Lines Expressing Different Progesterone Receptor Isotypes: Possible Involvement of Cadherins Reproductive Sciences, May 1, 2005; 12(4): 278 - 284. [Abstract] [PDF]

				E. Smid-Koopman, L. C. M. Kuhne, E. E. Hanekamp, S. C.J.P. Gielen, P. E. De Ruiter, J. A. Grootegoed, T. J.M. Helmerhorst, C. W. Burger, A. O. Brinkmann, F. J. Huikeshoven, et al. Progesterone-Induced Inhibition of Growth and Differential Regulation of Gene Expression in PRA- and/or PRB-Expressing Endometrial Cancer Cell Lines Reproductive Sciences, May 1, 2005; 12(4): 285 - 292. [Abstract] [PDF]

				D. Dai, L. Albitar, T. Nguyen, L. L. Laidler, M. Singh, and K. K. Leslie A therapeutic model for advanced endometrial cancer: Systemic progestin in combination with local adenoviral-mediated progesterone receptor expression Mol. Cancer Ther., January 1, 2005; 4(1): 169 - 175. [Abstract] [Full Text] [PDF]

				E. E Hanekamp, L. M Kuhne, J A. Grootegoed, C. W Burger, and L. J Blok Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice Endocr. Relat. Cancer, December 1, 2004; 11(4): 831 - 841. [Abstract] [Full Text] [PDF]